Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
232 Clinical Updates found
Biological Insights Fuel Novel Treatments for Rare Head and Neck Cancers
Biological Insights Fuel Novel Treatments for Rare Head and Neck Cancers (Part 1: Rare Salivary Cancers)

This three-part series summarizes MSK’s recent advances in clinical research and novel treatment approaches for rare head and neck cancers.
Biological Insights Fuel Novel Treatments for Rare Head and Neck Cancers
Biological Insights Fuel Novel Treatments for Rare Head and Neck Cancers (Part 2: Rare Thyroid Cancers)

This article is Part 2 of our three-part series on MSK-led advances for improving outcomes for patients with rare head and neck cancers.
Biological Insights Fuel Novel Treatments for Rare Non-Melanoma Skin and Oral Cavity Cancers
Biological Insights Fuel Novel Treatments for Rare Non-Melanoma Skin and Oral Cavity Cancers (Part 3)

This article is Part 3 of our three-part series summarizing how MSK’s biological insights and expertise fuel innovative treatment approaches for patients with rare head and neck cancers.
Salvage Surgery After Initial Nonoperative Treatment Increased Survival in Select Patients with Lung Cancer
Salvage Surgery After Initial Nonoperative Treatment Increased Survival in Select Patients with Lung Cancer

Lung resection after initial nonoperative treatment for non-small cell lung cancer (NSCLC) was safe and led to significantly improved survival in select patients previously treated with nonoperative therapies, according to a study by Memorial Sloan Kettering Cancer Center (MSK) investigators.
10 Trials and Growing: A Progress Update on the Thoracic Surgical Oncology Group Clinical Trials
10 Trials and Growing: A Progress Update on the Thoracic Surgical Oncology Group Clinical Trials

The Thoracic Surgery Oncology Group (TSOG) is a joint initiative between the American Association for Thoracic Surgery and the Fiona & Stanley Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center (MSK).
urologic surgeon Jose Flores, MD, MHA
ED Drugs Do Not Increase Risk of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

A new study by investigators at Memorial Sloan Kettering Cancer Center (MSK) found no evidence of an increased risk of biochemical recurrence with any PDE5 inhibitor use or duration in the first year following radical prostatectomy.
Rectal Cancer Response to Total Neoadjuvant Therapy Predicts Organ Preservation and Survival Outcomes
Rectal Cancer Response to Total Neoadjuvant Therapy Predicts Organ Preservation and Survival Outcomes

The Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial demonstrated that the watch-and-wait strategy is safe for patients with stage 2 and stage 3 rectal cancers that achieve a clinical complete response (CCR) or near-complete clinical response (NCR) to total neoadjuvant therapy (TNT).
MSK Kids 2023: Six Key Areas of Cancer Research and Clinical Advances
MSK Kids 2023: Six Key Areas of Cancer Research and Clinical Advances

Physicians and researchers at MSK Kids, Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, completed several groundbreaking research studies in 2023. These studies, which focused on pediatric disease mechanisms, paved the way to promising new therapeutic approaches for improving patient outcomes.
Dr. Cy Wilkins, Dr. Jae Park, Dr. Karthik Nath, Dr. Alina Markova, and Dr. Roni Shouval presented research related to managing and reducing treatment-related toxicities at the 2023 ASH meeting.
MSK ASH 2023 Insights: Managing and Reducing Treatment-Related Toxicities

Memorial Sloan Kettering Cancer Center (MSK) experts shared the results of their latest research at the 65th American Society of Hematology (ASH) Annual Meeting, held in San Diego, December 9 to 12, 2023.
Photo of the bispecific antibody CD20xCD3 in action against a Lymphoma cell
MSK ASH 2023 Insights: Promising Results for Bispecific Antibodies as First-Line Therapies for Patients with Follicular and B Cell Lymphoma

Bispecific antibodies bind to two antigens or two parts of the same antigen at the same time. The U.S. Food and Drug Administration (FDA) recently approved two CD20xCD3 bispecific antibodies —mosunetuzumab (mosun) for patients with relapsed or refractory follicular lymphoma and glofitamab (glofit) for patients with relapsed or refractory diffuse B cell lymphoma (DLBCL) or large B cell lymphoma (LBCL) treated with two or more prior lines of therapy.